The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms

What Was Tested

In this phase 4 trial, researchers set out to test Semaglutide.

The investigators plan to enroll 60 patients from the outpatient clinics or inpatient wards of the Metabolism and Cardiology departments who, within the past three months, have undergone coronary angiography for the treatment of coronary artery disease, are currently using sodium-glucose cotransporter-2 (SGLT-2) inhibitors for glycemic control, and have not received glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy for more than three months.

The effects after 6 months will be evaluated in terms of endothelial function, glycemic control indicators including glycemic variability assessed via continuous glucose monitoring (CGM), oxidative stress markers, and the incidence of symptomatic hypoglycemia.

It had three arms (groups): one (experimental), one (active comparator) and control (no intervention).

Continue previous standard treatment with add-on semaglutide.

Continue previous standard treatment with add-on semaglutide.

Continue previous standard treatment.

The registry classes the interventions as drug.

Who Took Part

Enrollment: 60 planned participants were the target.

It was open to people of any sex aged from 20 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Adults (\>=20 years old),. Type 2 Diabetes with coronary arterial disease underwent angioplasty within 3 months with SGLT2 inhibitors -.

The full record lists 2 inclusion and 4 exclusion criteria; among the exclusions: age\<20 years old,; pregnant women,; received glp-1 agonist in the recent 3 months -.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Everyone knew when Semaglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2025-10-01 with completion listed for 2028-07-31.

It ran at 1 site in Taiwan.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: change of Time-in-range (%) (time frame: From enrollment to the end of treatment at 24 weeks). change of HbA1c (time frame: From enrollment to the end of treatment at 24 weeks). change of Flow-Mediated Dilatation (FMD) (time frame: From enrollment to the end of treatment at 24 weeks).

It also tracked 4 secondary outcomes, for example change of serum ROS measurements, change of Peripheral Arterial Tonometry (PAT), Hypoglycemic episodes and change of fasting glucose.

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Semaglutide in 60 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.